AGP Executive Report
Last update: 25 minutes agoEbola Drug Trial Push (Africa): Mauritius-headquartered Xylomed Pharmaceuticals says it’s preparing a double-blind, randomised clinical trial for an experimental Ebola therapeutic, targeting DRC, Uganda and South Sudan, after lab work suggested the medicine can stop the virus from replicating. Microplastics Monitoring (Regional Health): Scientists from 21 African countries met in Accra to harmonise coastal microplastics monitoring protocols using nuclear and isotopic techniques, aiming for comparable data to guide evidence-based environmental and health policies. Local Talent Spotlight (Mauritius): Namibian healthcare student Maxine “Magano” Nauyala, studying at Polytechnic Mauritius, is building an international modelling profile while competing in Mauritius Model of the Month. Governance & Health System Risk (Mauritius): An opinion piece flags Mauritius’ pension reform delays and policy reversals as a wider governance problem that could strain welfare planning. Clean Energy With Health Links (Mauritius ties): Aditya Birla Group’s planned acquisition of Shell’s Mauritius-based Sprng Energy holding company expands a renewable portfolio of about 5 GWp, with potential long-term public health benefits via cleaner power.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.